278 related articles for article (PubMed ID: 22377247)
1. Role of oxidative stress in cardiovascular effects of anemia treatment with erythropoietin in predialysis patients with chronic kidney disease.
Martinez-Vea A; Marcas L; Bardají A; Romeu M; Gutierrez C; García C; Compte T; Nogues R; Peralta C; Giralt M
Clin Nephrol; 2012 Mar; 77(3):171-81. PubMed ID: 22377247
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis.
Parfrey PS; Lauve M; Latremouille-Viau D; Lefebvre P
Clin J Am Soc Nephrol; 2009 Apr; 4(4):755-62. PubMed ID: 19339417
[TBL] [Abstract][Full Text] [Related]
3. Contribution of anemia and hypertension to left ventricular hypertrophy during the initial 2 years after renal transplantation.
Ibernon M; Moreso F; Ruiz-Majoral A; Sarrias X; Sarrias M; Grinyó JM; Serón D
Transplant Proc; 2011; 43(6):2199-204. PubMed ID: 21839233
[TBL] [Abstract][Full Text] [Related]
4. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
Thanakitcharu P; Siriwiwatanakul N
J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
[TBL] [Abstract][Full Text] [Related]
6. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
[TBL] [Abstract][Full Text] [Related]
7. Italian randomized trial of hemoglobin maintenance to prevent or delay left ventricular hypertrophy in chronic kidney disease.
Cianciaruso B; Ravani P; Barrett BJ; Levin A;
J Nephrol; 2008; 21(6):861-70. PubMed ID: 19034870
[TBL] [Abstract][Full Text] [Related]
8. Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD.
Eckardt KU; Scherhag A; Macdougall IC; Tsakiris D; Clyne N; Locatelli F; Zaug MF; Burger HU; Drueke TB
J Am Soc Nephrol; 2009 Dec; 20(12):2651-60. PubMed ID: 19850955
[TBL] [Abstract][Full Text] [Related]
9. Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease.
Minutolo R; Chiodini P; Cianciaruso B; Pota A; Bellizzi V; Avino D; Mascia S; Laurino S; Bertino V; Conte G; De Nicola L
Clin J Am Soc Nephrol; 2009 Mar; 4(3):552-9. PubMed ID: 19261821
[TBL] [Abstract][Full Text] [Related]
10. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
Nurko S; Spirko R; Law A; Dennis VW
Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
[TBL] [Abstract][Full Text] [Related]
11. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD.
Levin A; Djurdjev O; Thompson C; Barrett B; Ethier J; Carlisle E; Barre P; Magner P; Muirhead N; Tobe S; Tam P; Wadgymar JA; Kappel J; Holland D; Pichette V; Shoker A; Soltys G; Verrelli M; Singer J
Am J Kidney Dis; 2005 Nov; 46(5):799-811. PubMed ID: 16253719
[TBL] [Abstract][Full Text] [Related]
12. Risk factors associated with increased left ventricular mass index in chronic kidney disease patients evaluated using echocardiography.
Matsumoto M; Io H; Furukawa M; Okumura K; Masuda A; Seto T; Takagi M; Sato M; Nagahama L; Omote K; Hisada A; Horikoshi S; Tomino Y
J Nephrol; 2012; 25(5):794-801. PubMed ID: 22241636
[TBL] [Abstract][Full Text] [Related]
13. [Improvement of left ventricular hypertrophy by anemic-correcting erythropoietin therapy in chronic renal insufficiency].
Jiang JP; Hou FF; Gao LZ; Pan YB; Yang NS; Chen W; Shu GY; Chen YM; Chen J; Peng WH; Wu JP; Yang ZM
Zhonghua Nei Ke Za Zhi; 2005 Jan; 44(1):25-9. PubMed ID: 15769393
[TBL] [Abstract][Full Text] [Related]
14. Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient.
Schmid H; Schiffl H; Lederer SR
Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):465-70. PubMed ID: 21738032
[TBL] [Abstract][Full Text] [Related]
15. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL.
Ayus JC; Go AS; Valderrabano F; Verde E; de Vinuesa SG; Achinger SG; Lorenzo V; Arieff AI; Luño J;
Kidney Int; 2005 Aug; 68(2):788-95. PubMed ID: 16014057
[TBL] [Abstract][Full Text] [Related]
16. Effect of anemia correction on left ventricular hypertrophy in patients with modestly high hemoglobin level and chronic kidney disease .
Akaishi M; Hiroe M; Hada Y; Suzuki M; Tsubakihara Y; Akizawa T;
J Cardiol; 2013 Oct; 62(4):249-56. PubMed ID: 23787155
[TBL] [Abstract][Full Text] [Related]
17. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters.
Kirkpantur A; Kahraman S; Yilmaz R; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
Artif Organs; 2005 Dec; 29(12):965-72. PubMed ID: 16305652
[TBL] [Abstract][Full Text] [Related]
18. Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease.
Foley RN; Curtis BM; Randell EW; Parfrey PS
Clin J Am Soc Nephrol; 2010 May; 5(5):805-13. PubMed ID: 20378644
[TBL] [Abstract][Full Text] [Related]
19. Hemorheological and hemodynamic changes in predialysis patients after normalization of hemoglobin with epoetin-alpha.
Furuland H; Linde T; Sandhagen B; Andrén B; Wikström B; Danielson BG
Scand J Urol Nephrol; 2005; 39(5):399-404. PubMed ID: 16257842
[TBL] [Abstract][Full Text] [Related]
20. Renovascular protective effects of erythropoietin in patients with chronic kidney disease.
Fujiwara N; Nakamura T; Sato E; Kawagoe Y; Hikichi Y; Ueda Y; Node K
Intern Med; 2011; 50(18):1929-34. PubMed ID: 21921371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
